Fiche publication
Date publication
juin 2023
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr KALBACHER Elsa
Tous les auteurs :
Selle F, Joly F, Gladieff L, Prulhière K, Leary A, Kalbacher E, Rouleau E, Ray-Coquard I
Lien Pubmed
Résumé
Management of high grade, serous and/or endometrioid, advanced (stages III-IV) ovarian carcinomas and HRD-BRCA testing in 2023: update according to data published/presented in 2022 Molecular analysis of ovarian carcinomas must be now systematically performed to determine BRCA1 and BRCA2 status as well as genomic instability score. Several types of tests are available. From a clinical perspective, new data from phase III clinical trials presented in 2022 confirm the key role of PARP inhibitors in first-line medical treatment of high-grade serous ovarian cancers. A new algorithm that includes all new evidence is proposed for selection of first-line therapy.
Mots clés
Analyse moléculaire, BRCA status, Cancer ovaire, Genomic instability score, High grade advanced, Inhibiteurs de PARP, Molecular analysis, PARP inhibitors, Score d'instabilité, Statut BRCA, génomique, haut grade avancé, ovarian cancer
Référence
Bull Cancer. 2023 06;110(6S):6S5-6S9
